Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma

Next Previous
Trial Profile

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mezigdomide (Primary) ; Selinexor (Primary) ; Belantamab mafodotin; Bortezomib; Carfilzomib; Clarithromycin; Daratumumab; Dexamethasone; Elotuzumab; Ixazomib; Lenalidomide; Pomalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms STOMP
  • Sponsors Karyopharm Therapeutics

Most Recent Events

  • 06 Dec 2024 According to a Kymera Therapeutics media release, the John Theurer Cancer Center Researchers to present data from this trial at the 66th Annual Meeting of the American Society of Hematology (ASH) to be held in San Diego, California, from December 7-10, 2024.
  • 19 Sep 2024 Status changed from active, no longer recruiting to recruiting.
  • 31 May 2024 According to a Karyopharm Therapeutics media release, data from the study presented at Frontiers of Oncology Journal

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top